MDxHealth S.A.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MDxHealth S.A. is a commercial-stage precision diagnostics company specializing in molecular diagnostic tests focused on the personalized diagnosis and treatment of prostate cancer and other urologic diseases. The company’s core products include SelectMDx, a non-invasive urine biomarker test that helps assess the risk of aggressive prostate cancer; ConfirmMDx, an epigenetic tissue-based assay that aids in prostate cancer diagnosis; and other molecular diagnostic tests based on proprietary genetic, epigenetic, and complex molecular technologies. MDxHealth operates clinical laboratories and provides testing services primarily in the United States and Europe. Founded in 2003 and headquartered in Herstal, Belgium, MDxHealth also leverages its DNA methylation-specific PCR platform to develop its portfolio of tests. The company’s tests assist physicians in diagnosing cancer, predicting recurrence risks, and forecasting responses to specific therapies. In recent developments, MDxHealth completed the acquisition of the Exosome Diagnostics business from Bio-Techne in 2025, which included the ExoDx Prostate test and a CLIA-certified clinical laboratory, expanding its molecular diagnostic capabilities in prostate cancer detection. The acquisition entailed a $15 million agreement with payment installments structured over several years. Additionally, MDxHealth secured growth capital through a $100 million loan and security agreement with OrbiMed Advisors in 2024, providing enhanced financial flexibility to support market demand and expansion. The company reported strong revenue growth, with 2024 revenues reaching $90 million, a 28% increase compared to 2023, alongside improved adjusted EBITDA. MDxHealth continues focusing on precision diagnostic innovations and expanding its urology market presence through strategic investments and product development.
MDxHealth Q1 Earnings Call Highlights
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Mdxhealth Reports Q1-2026 Results
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
Brokerages Set MDxHealth SA (NASDAQ:MDXH) PT at $7.75
Health Catalyst (NASDAQ:HCAT) versus MDxHealth (NASDAQ:MDXH) Head to Head Comparison
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of “Moderate Buy” by Analysts
MDxHealth SA (NASDAQ:MDXH) Receives $7.75 Average Target Price from Brokerages
MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going
Angle PLC Announces Strategy Update
MDxHealth SA (MDXH) Reports Q2 Loss, Tops Revenue Estimates
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript